Kamada (NASDAQ:KMDA) Coverage Initiated at Benchmark

Stock analysts at Benchmark assumed coverage on shares of Kamada (NASDAQ:KMDA) in a research report issued to clients and investors on Friday, Marketbeat reports. The brokerage set a “buy” rating and a $15.00 price target on the biotechnology company’s stock. Benchmark’s target price indicates a potential upside of 123.21% from the stock’s previous close.

KMDA has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Kamada in a report on Thursday, March 6th. StockNews.com raised shares of Kamada from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 13th.

Kamada Trading Up 1.1 %

NASDAQ KMDA opened at $6.72 on Friday. The firm’s fifty day simple moving average is $7.19 and its two-hundred day simple moving average is $6.25. Kamada has a 12-month low of $4.74 and a 12-month high of $9.16. The firm has a market capitalization of $386.27 million, a P/E ratio of 24.00, a P/E/G ratio of 0.97 and a beta of 0.97.

Institutional Investors Weigh In On Kamada

A number of large investors have recently made changes to their positions in KMDA. Public Employees Retirement System of Ohio purchased a new stake in shares of Kamada during the third quarter valued at $77,000. JPMorgan Chase & Co. purchased a new stake in shares of Kamada during the fourth quarter valued at $67,000. NewEdge Advisors LLC grew its holdings in shares of Kamada by 54.2% during the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 8,260 shares during the last quarter. Aristides Capital LLC grew its holdings in shares of Kamada by 12.1% during the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after buying an additional 6,850 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after buying an additional 1,549 shares during the last quarter. 20.38% of the stock is owned by hedge funds and other institutional investors.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.